Methods: 24 patients with uveitis taking etanercept and 21 taking infliximab were studied. The endpoint ophthalmological evaluation was at 24 months or at the termination of the first biological agent ...

FutureWise Research, a leading provider of market intelligence and consulting services in the healthcare industry, is pleased to announce the release of its latest in-depth market analysis report, ...

No significant difference in the risk of serious infections between etanercept and infliximab biosimilars and their original brand-name medications was identified. Patients treated with etanercept and ...

Study results suggested infliximab and etanercept biosimilars have similar safety profiles to their bio-originator products. The incidence of serious infection among patients receiving infliximab and ...

An analysis of 25 studies found adalimumab, infliximab, and etanercept biosimilars were considered just as safe, effective, and tolerable compared with their originators in the treatment of rheumatoid ...

Under the first phase of these switching policies, individuals living with inflammatory arthritis and psoriasis and receiving reference etanercept and infliximab were given 6 months to switch to ...

New York, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2023" - https ...

Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com ...